Overview

A Study of Cabiralizumab Given With Nivolumab With and Without Chemotherapy in Patients With Advanced Pancreatic Cancer

Status:
Active, not recruiting

Trial end date:
2022-07-01

Target enrollment:

Participant gender:

Summary

The purpose of this study is to determine whether an investigational immuno-therapy, cabiralizumab in combination with nivolumab, with or without chemotherapy, is effective for the treatment of advanced pancreatic cancer.

Phase:

Phase 2

Details

Lead Sponsor:

Bristol-Myers Squibb

Treatments:

Albumin-Bound Paclitaxel
Antibodies, Monoclonal
Fluorouracil
Gemcitabine
Irinotecan
Leucovorin
Nivolumab
Oxaliplatin
Paclitaxel